Biogen (BIIB) Notes Payables (2009 - 2025)

Biogen (BIIB) has reported Notes Payables for 12 consecutive years, with $6.3 billion the latest figure, recorded in Q3 2025.

• In Q3 2025, Notes Payables rose 259.54% year-over-year to $6.3 billion; the TTM figure through Sep 2025 stood at $6.3 billion (up 259.54% YoY), while the FY2024 annual figure was $1.7 billion, down 74.8% from the prior year.
• Notes Payables came in at $6.3 billion for Q3 2025 at Biogen, up from $1.7 billion in the prior quarter.
• The five-year high for Notes Payables was $7.3 billion in Q2 2022, with the low at $250.0 million in Q1 2024.
• Average Notes Payables over 5 years is $4.2 billion, with a median of $6.3 billion recorded in 2022.
• Across the five-year window, Notes Payables tumbled 74.8% in 2024 and jumped 599.64% in 2025, its largest moves.
• Year by year, Notes Payables stood at $999.1 million in 2021, then surged by 528.67% to $6.3 billion in 2022, then rose by 10.46% to $6.9 billion in 2023, then sank by 74.8% to $1.7 billion in 2024, then surged by 259.44% to $6.3 billion in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $6.3 billion, $1.7 billion, and $1.7 billion for Q3 2025, Q1 2025, and Q4 2024 respectively.